References

Leishmaniasis

10.1016/s0140-6736(18)31204-2 · 2018 · External reference

Protection and pathology in Leishmania braziliensis infection

10.3390/pathogens11040466 · 2022 · External reference

Cutaneous leishmaniasis: immune responses in protection and pathogenesis

10.1038/nri.2016.72 · 2016 · External reference

Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline

10.4269/ajtmh.12-0729 · 2014 · External reference

Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer

10.1086/340526 · 2002 · External reference

Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil

10.4269/ajtmh.2009.80.574 · 2009 · External reference

Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis

10.1016/j.jid.2020.07.011 · 2021 · External reference

Helminth infections and allergic diseases: Systematic review and meta-analysis of the global literature

10.1016/j.jaci.2021.12.777 · 2022 · External reference

Low frequency of positive skin tests in asthmatic patients infected with Schistosoma mansoni exposed to high levels of mite allergens

10.1046/j.1399-3038.2003.00119.x · 2004 · External reference

Schistosoma mansoni antigens modulate the allergic response in a murine model of ovalbumin-induced airway inflammation

10.1111/j.1365-2249.2009.04084.x · 2010 · External reference

Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection

10.1371/journal.pntd.0000308 · 2008 · External reference

Antibody response against schistosomulum surface antigens and protective immunity following immunization with highly irradiated cercariae of Schistosoma mansoni

10.1111/j.1365-3024.1985.tb00065.x · 1985 · External reference

Schistosoma mansoni antigens alter activation markers and cytokine profile in lymphocytes of patients with asthma

10.1016/j.actatropica.2016.12.002 · 2017 · External reference

Schistosoma mansoni antigens alter the cytokine response in vitro during cutaneous leishmaniasis

10.1590/s0074-02762011000700012 · 2011 · External reference

A double edged sword: Schistosoma mansoni Sm29 regulates both Th1 and Th2 responses in inflammatory mucosal diseases

10.1038/mi.2016.69 · 2016 · External reference

Dendritic cell profile induced by Schistosoma mansoni antigen in cutaneous leishmaniasis patients

10.1155/2014/743069 · 2014 · External reference

Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled trial

10.1016/j.ijid.2024.107206 · 2024 · External reference

The growing role of nanotechnology in combating infectious disease

10.4161/viru.2.5.17035 · 2011 · External reference

Efficacy and immune response elicited by gold nanoparticle- based nanovaccines against infectious diseases

10.3390/vaccines10040505 · 2022 · External reference

Schistosoma mansoni antigen-driven interleukin-10 production in infected asthmatic individuals

10.1590/s0074-02762006000900055 · 2006 · External reference

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

10.1038/227680a0 · 1970 · External reference

The use of gold nanorods as a new vaccine platform against schistosomiasis

10.1016/j.jconrel.2018.02.004 · 2018 · External reference

Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis

10.1128/iai.73.9.5827-5834.2005 · 2005 · External reference

Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous Leishmaniasis

10.4269/ajtmh.16-0435 · 2017 · External reference

Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials

10.4269/ajtmh.2005.73.79 · 2005 · External reference

Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony

10.4269/ajtmh.2001.65.87 · 2001 · External reference

Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis

10.1086/315082 · 1999 · External reference

Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications

2017 · External reference

Gold nanoparticles in delivery applications

10.1016/j.addr.2008.03.016 · 2008 · External reference

Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a Schistosoma mansoni infection

10.1371/journal.pntd.0003537 · 2015 · External reference

DNA vaccine encoding the chimeric form of Schistosoma mansoni Sm-TSP2 and Sm29 confers partial protection against challenge infection

10.1371/journal.pone.0125075 · 2015 · External reference

A strong humoral immune response induced by a vaccine formulation containing rSm29 adsorbed to alum is associated with protection against Schistosoma mansoni reinfection in mice

10.3389/fimmu.2018.02488 · 2018 · External reference

Clinically translatable gold nanozymes with broad spectrum antioxidant and anti-inflammatory activity for alleviating acute kidney injury

10.7150/thno.66518 · 2021 · External reference

CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production

10.1371/journal.ppat.1006196 · 2017 · External reference

Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis

10.1371/journal.ppat.1003504 · 2013 · External reference

Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in Leishmania braziliensis infection

10.1016/j.jid.2019.05.025 · 2020 · External reference